Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Viral-bacterial coinfection affects the presentation and alters the prognosis of severe community-acquired pneumonia.

Voiriot G, Visseaux B, Cohen J, Nguyen LB, Neuville M, Morbieu C, Burdet C, Radjou A, Lescure FX, Smonig R, Armand-Lefèvre L, Mourvillier B, Yazdanpanah Y, Soubirou JF, Ruckly S, Houhou-Fidouh N, Timsit JF.

Crit Care. 2016 Oct 25;20(1):375.

2.

Adjunctive Corticotherapy for Community Acquired Pneumonia: A Systematic Review and Meta-Analysis.

Marti C, Grosgurin O, Harbarth S, Combescure C, Abbas M, Rutschmann O, Perrier A, Garin N.

PLoS One. 2015 Dec 7;10(12):e0144032. doi: 10.1371/journal.pone.0144032. Review.

3.

Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study.

Rautanen A, Mills TC, Gordon AC, Hutton P, Steffens M, Nuamah R, Chiche JD, Parks T, Chapman SJ, Davenport EE, Elliott KS, Bion J, Lichtner P, Meitinger T, Wienker TF, Caulfield MJ, Mein C, Bloos F, Bobek I, Cotogni P, Sramek V, Sarapuu S, Kobilay M, Ranieri VM, Rello J, Sirgo G, Weiss YG, Russwurm S, Schneider EM, Reinhart K, Holloway PA, Knight JC, Garrard CS, Russell JA, Walley KR, Stüber F, Hill AV, Hinds CJ; ESICM/ECCRN GenOSept Investigators..

Lancet Respir Med. 2015 Jan;3(1):53-60. doi: 10.1016/S2213-2600(14)70290-5.

4.

Overexpression of activated protein C hampers bacterial dissemination during pneumococcal pneumonia.

de Boer JD, Kager LM, Roelofs JJ, Meijers JC, de Boer OJ, Weiler H, Isermann B, van 't Veer C, van der Poll T.

BMC Infect Dis. 2014 Nov 4;14:559. doi: 10.1186/s12879-014-0559-3.

5.

Recombinant human activated protein C in the treatment of acute respiratory distress syndrome: a randomized clinical trial.

Cornet AD, Groeneveld AB, Hofstra JJ, Vlaar AP, Tuinman PR, van Lingen A, Levi M, Girbes AR, Schultz MJ, Beishuizen A.

PLoS One. 2014 Mar 14;9(3):e90983. doi: 10.1371/journal.pone.0090983.

6.

Severity assessment of lower respiratory tract infection in Malawi: derivation of a novel index (SWAT-Bp) which outperforms CRB-65.

Birkhamshaw E, Waitt CJ, Innes M, Waitt PI.

PLoS One. 2013 Dec 6;8(12):e82178. doi: 10.1371/journal.pone.0082178.

7.

Protease-activated receptor-1 impairs host defense in murine pneumococcal pneumonia: a controlled laboratory study.

Schouten M, van't Veer C, Roelofs JJ, Levi M, van der Poll T.

Crit Care. 2012 Dec 27;16(6):R238. doi: 10.1186/cc11910.

8.

Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study.

Mongardon N, Max A, Bouglé A, Pène F, Lemiale V, Charpentier J, Cariou A, Chiche JD, Bedos JP, Mira JP.

Crit Care. 2012 Aug 15;16(4):R155. doi: 10.1186/cc11471.

9.

Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated).

Annane D, Mira JP, Ware LB, Gordon AC, Sevransky J, Stüber F, Heagerty PJ, Wellman HF, Neira M, Mancini ADj, Russell JA.

Ann Intensive Care. 2012 Jun 13;2(1):15. doi: 10.1186/2110-5820-2-15.

10.

Nebulized anticoagulants for acute lung injury - a systematic review of preclinical and clinical investigations.

Tuinman PR, Dixon B, Levi M, Juffermans NP, Schultz MJ.

Crit Care. 2012 Dec 12;16(2):R70. doi: 10.1186/cc11325. Review.

11.

Defining severe pneumonia.

Brown SM, Dean NC.

Clin Chest Med. 2011 Sep;32(3):469-79. doi: 10.1016/j.ccm.2011.05.001. Review.

12.

Community-acquired pneumonia in elderly patients.

Stupka JE, Mortensen EM, Anzueto A, Restrepo MI.

Aging health. 2009;5(6):763-774.

13.

Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: a controlled laboratory study.

Schouten M, van't Veer C, Roelofs JJ, Levi M, van der Poll T.

Crit Care. 2010;14(4):R145. doi: 10.1186/cc9213.

14.

Infection rate and acute organ dysfunction risk as explanations for racial differences in severe sepsis.

Mayr FB, Yende S, Linde-Zwirble WT, Peck-Palmer OM, Barnato AE, Weissfeld LA, Angus DC.

JAMA. 2010 Jun 23;303(24):2495-503. doi: 10.1001/jama.2010.851.

15.

Activated protein C for H1N1 influenza? More work to do!

LaRosa SP.

Crit Care. 2010;14(3):156. doi: 10.1186/cc8994.

16.

Bench-to-bedside review: bacterial pneumonia with influenza - pathogenesis and clinical implications.

van der Sluijs KF, van der Poll T, Lutter R, Juffermans NP, Schultz MJ.

Crit Care. 2010;14(2):219. doi: 10.1186/cc8893. Review.

17.

Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study.

Schouten M, Sluijs KF, Gerlitz B, Grinnell BW, Roelofs JJ, Levi MM, van 't Veer C, van der Poll T.

Crit Care. 2010;14(2):R65. doi: 10.1186/cc8964.

18.

Defining and predicting severe community-acquired pneumonia.

Brown SM, Dean NC.

Curr Opin Infect Dis. 2010 Apr;23(2):158-64. doi: 10.1097/QCO.0b013e3283368333. Review.

19.

Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats.

Hofstra JJ, Cornet AD, de Rooy BF, Vlaar AP, van der Poll T, Levi M, Zaat SA, Schultz MJ.

Crit Care. 2009;13(5):R145. doi: 10.1186/cc8040.

20.
Items per page

Supplemental Content

Support Center